Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
Source: View publication →
The iPrEx trial demonstrated that a daily oral combination of emtricitabine and tenofovir disoproxil fumarate (FTC-TDF) significantly reduces the risk of HIV acquisition in high-risk men and transgender women who have sex with men, with efficacy strongly dependent on medication adherence.
Key Findings
Study Design
Study Limitations
Clinical Significance
The iPrEx trial was a landmark study that revolutionized modern HIV prevention by providing the first definitive clinical evidence for the efficacy of pre-exposure prophylaxis (PrEP). Its findings directly led to the 2012 FDA approval of Truvada for HIV prevention, ushering in an era of biomedical prophylaxis that shifted the global paradigm beyond solely behavioral interventions (e.g., condoms). By demonstrating a stark contrast between an overall 44% risk reduction and a 92% reduction among participants with detectable drug levels, the trial established medication adherence as the absolute critical determinant of PrEP success—a principle that has guided all subsequent clinical implementation and catalyzed the development of long-acting prevention modalities.
Historical Context
Prior to 2010, the global response to the HIV epidemic relied almost exclusively on behavioral modifications, condom distribution, testing, and treating known infected individuals to reduce transmission (treatment as prevention). Biomedical prevention strategies for uninfected individuals, such as topical microbicides and HIV vaccines, had historically yielded disappointing or merely modest results (e.g., the RV144 vaccine trial). The concept of giving daily systemic antiretroviral therapy to uninfected, high-risk individuals to prevent viral establishment was theoretically sound but lacked definitive human data. The iPrEx trial was launched in 2007 across 6 countries to test this hypothesis in MSM, a population disproportionately affected by the epidemic.
Guided Discussion
High-yield insights from every perspective
What is the mechanism of action of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), and why are two agents used together for pre-exposure prophylaxis rather than a single agent?
Key Response
FTC and TDF are both nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that competitively inhibit viral reverse transcriptase and cause chain termination. Using two agents provides a higher barrier to resistance and synergistic antiviral activity compared to monotherapy, crucial for preventing establishment of infection if exposure occurs.
When initiating a patient on FTC-TDF for PrEP based on the iPrEx trial, what baseline testing and ongoing clinical monitoring are essential to ensure patient safety and prevent medication-associated complications?
Key Response
Baseline and quarterly HIV testing are critical to avoid PrEP use during unrecognized acute HIV, which can lead to resistant strains. Additionally, baseline renal function and HBV serology must be assessed, as TDF can cause nephrotoxicity and its discontinuation can precipitate severe acute exacerbation of hepatitis B.
The iPrEx trial showed a strong correlation between detectable drug levels and HIV protection. How does the pharmacokinetic profile of TDF/FTC differ in rectal versus vaginal tissues, and how does this impact adherence counseling for MSM compared to heterosexual women?
Key Response
TDF/FTC concentrates much faster and achieves higher, more stable active diphosphate levels in rectal tissue compared to cervicovaginal tissue. Consequently, PrEP provides robust protection for receptive anal intercourse with fewer doses per week (estimated 4 doses/week), whereas near-perfect daily adherence is required for optimal protection during receptive vaginal intercourse.
Given the high efficacy of PrEP in highly adherent patients, risk compensation (increased unprotected sex) was a major concern prior to the iPrEx trial. How did the trial findings address this concern, and how should this influence how we frame PrEP discussions with hesitant colleagues?
Key Response
The iPrEx trial actually showed a decrease in self-reported unprotected receptive anal intercourse and an increase in condom use over time in both study arms. This suggests that engaging in a PrEP program, which includes regular counseling and STI testing, does not necessarily lead to risk compensation and may actually reinforce overall safe sexual practices, a key teaching point for providers hesitant to prescribe it.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In the iPrEx trial, adherence was measured via self-report, pill counts, and drug-level testing in a subset of participants. How does the discrepancy between self-reported adherence and objective pharmacokinetic data highlight the limitations of traditional adherence measures in prevention trials, and what novel trial designs could mitigate this bias?
Key Response
Self-reported adherence in iPrEx was nearly perfectly high, yet drug-level testing revealed that only a fraction of those who acquired HIV had detectable drug levels. This demonstrates significant social desirability bias. Future trials could utilize objective biomarkers (e.g., intra-erythrocytic drug levels) as primary covariates in adherence-efficacy models or employ directly observed long-acting formulations to eliminate the daily adherence variable entirely.
The iPrEx trial utilized an intent-to-treat (ITT) analysis to demonstrate a 44% overall reduction in HIV incidence, but the reduction was much higher (92%) in the subgroup with detectable drug levels. As a reviewer, what are the epidemiological hazards of highlighting the 92% efficacy figure in the abstract or conclusions?
Key Response
Highlighting the 92% efficacy derived from the subset with detectable drug levels constitutes a per-protocol or as-treated analysis, which breaks the randomization and introduces confounding (e.g., highly adherent patients might also engage in lower-risk behaviors). As an editor, one must ensure the primary ITT results (44% reduction) remain the focal point to accurately reflect real-world population-level effectiveness and avoid overstating the drug's practical impact.
The iPrEx trial provided the foundational evidence for CDC and WHO guidelines recommending daily oral FTC-TDF for PrEP in MSM. How should guideline committees weigh the advent of on-demand (2-1-1) PrEP dosing and long-acting injectables (like cabotegravir) against the established iPrEx daily oral paradigm?
Key Response
While iPrEx established daily FTC-TDF as a Category 1A recommendation, subsequent trials (like IPERGAY for 2-1-1 dosing and HPTN 083 for long-acting cabotegravir) offer alternatives that address the adherence challenges highlighted in iPrEx. Guidelines must now stratify PrEP recommendations based on patient preference, adherence capacity, and sexual practices, maintaining daily FTC-TDF as a standard while upgrading alternatives to high-strength recommendations to maximize population coverage.
Clinical Landscape
Noteworthy Related Trials
Partners PrEP Trial
Tested
Daily oral TDF or TDF-FTC
Population
Heterosexual HIV serodiscordant couples
Comparator
Placebo
Endpoint
HIV infection
PROUD Trial
Tested
Daily oral TDF-FTC
Population
MSM at high risk for HIV
Comparator
Deferred PrEP
Endpoint
HIV infection
IPERGAY Trial
Tested
Event-driven (on-demand) oral TDF-FTC
Population
High-risk MSM
Comparator
Placebo
Endpoint
HIV infection
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis